Trial intelligence / Profile preview

Phase 3 outpatient remdesivir trial for early COVID-19

2020-003510-12Phase 3Completed

Sponsor
Gilead Sciences
Start
Aug 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir with Placebo (2 arms). Started Aug 2020; status: completed.

02

Drugs

remdesivir
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on 2020-003510-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-003510-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call